A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints

By Whitehead John  

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 6, 2007-11 ,pp. : 1117-1129

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations

By Ivanova Anastasia  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 2, 2009-03 ,pp. : 247-255

Taylor & Francis Ltd

Access to resources Recommend Favorite

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

By Traynor Anne   Gordon Michael   Alberti Dona   Mendelson David   Munsey Mark   Wilding George   Gammans Richard   Read William  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 509-515

Springer Publishing Company

Access to resources Recommend Favorite